• Explore /
  • Poster
  • / A Phase II Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients with Malignant Melanoma Pre-Treated with Recombinant CDX-301, a Recombinant Human Flt3 Ligand.

A Phase II Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients with Malignant Melanoma Pre-Treated with Recombinant CDX-301, a Recombinant Human Flt3 Ligand.

Abstract Poster

Authors

null

Nina Bhardwaj

Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

Nina Bhardwaj , Anna C. Pavlick , Marc S. Ernstoff , Brent Allen Hanks , Mark R. Albertini , Jason John Luke , Michael Jay Yellin , Tibor Keler , Thomas A. Davis , Andrea Crocker , Laura Vitale , Chihiro Morishima , Philip Adam Friedlander , Martin A. Cheever , Steven Fling

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Other Melanoma/Skin Cancers

Clinical Trial Registration Number

NCT02129075

Citation

J Clin Oncol 34, 2016 (suppl; abstr 9589)

DOI

10.1200/JCO.2016.34.15_suppl.9589

Abstract #

9589

Poster Bd #

194

Abstract Disclosures

Similar Posters

First Author: Anna C. Pavlick

First Author: Jonathan S. Cebon

First Author: Yasuyoshi Sato

Poster

2016 ASCO Annual Meeting

Retrospective cohort analysis of adjuvant NY-ESO-1 vaccines in stage III melanoma.

Retrospective cohort analysis of adjuvant NY-ESO-1 vaccines in stage III melanoma.

First Author: Michael William Lattanzi